Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for EYEPOINT PHARMACEUTICALS, INC. (EYPT : NSDQ)

• Company Description    EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. Number of Employees: 165

• Price / Volume Information    Yesterday's Closing Price: $12.25 Daily Weekly Monthly 20 Day Moving Average: 1,407,823 shares Shares Outstanding: 68.93 (millions) Market Capitalization: $844.36 (millions) Beta: 1.95 52 Week High: $14.91 52 Week Low: $3.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.98% -16.50% 12 Week 12.49% 2.83% Year To Date 64.43% 40.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 480 PLEASANT STREET - WATERTOWN,MA 02472 USA ph: 617-926-5000 fax: 617-926-5050 eyepoint@sternir.com http://www.eyepointpharma.com

• General Corporate Information    Officers Jay S. Duker - President; Chief Executive Officer and Director Goran Ando - Chairman Nancy Lurker - Vice Chairman George O. Elston - Executive Vice President and Chief Financial Offic Wendy DiCicco - Director Peer Information EYEPOINT PHARMACEUTICALS, INC. (CORR.) EYEPOINT PHARMACEUTICALS, INC. (RSPI) EYEPOINT PHARMACEUTICALS, INC. (CGXP) EYEPOINT PHARMACEUTICALS, INC. (BGEN) EYEPOINT PHARMACEUTICALS, INC. (GTBP) EYEPOINT PHARMACEUTICALS, INC. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30233G209 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 68.93 Most Recent Split Date: 12.00 (0.10:1) Beta: 1.95 Market Capitalization: $844.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.43 Price/Cash Flow: - Price / Sales: 16.27 EPS Growth vs. Year Ago Period: -46.55% vs. Previous Quarter: -30.77% Sales Growth vs. Year Ago Period: -43.73% vs. Previous Quarter: -78.19% ROE 09/30/25 - - 06/30/25 - -63.80 03/31/25 - -54.27 ROA 09/30/25 - - 06/30/25 - -50.72 03/31/25 - -41.75 Current Ratio 09/30/25 - - 06/30/25 - 8.00 03/31/25 - 7.85 Quick Ratio 09/30/25 - - 06/30/25 - 7.91 03/31/25 - 7.79 Operating Margin 09/30/25 - - 06/30/25 - -337.93 03/31/25 - -261.91 Net Margin 09/30/25 - - 06/30/25 - -337.93 03/31/25 - -261.91 Pre-Tax Margin 09/30/25 - - 06/30/25 - -337.58 03/31/25 - -261.75 Book Value 09/30/25 - - 06/30/25 - 3.58 03/31/25 - 4.34 Inventory Turnover 09/30/25 - - 06/30/25 - 1.02 03/31/25 - 1.38 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©